Exploiting synthetic lethal interactions for targeted cancer therapy
Open Access
- 28 October 2009
- journal article
- research article
- Published by Taylor & Francis in Cell Cycle
- Vol. 8 (19) , 3112-3119
Abstract
Emerging data suggests that synthetic lethal interactions between mutated oncogenes/tumor suppressor genes and molecules involved in DNA damage signaling and repair can be therapeutically exploited to preferentially kill tumor cells. In this review, we discuss the concept of synthetic lethality, and describe several recent examples in which this concept was successfully implemented to target tumor cells in culture, in mouse models, and in human cancer patients.Keywords
This publication has 93 references indexed in Scilit:
- Essential Role for DNA-PKcs in DNA Double-Strand Break Repair and Apoptosis in ATM-Deficient LymphocytesMolecular Cell, 2009
- A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras OncogeneCell, 2009
- Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2Current Opinion in Cell Biology, 2009
- Principles of Cancer Therapy: Oncogene and Non-oncogene AddictionCell, 2009
- Impact of mutant p53 functional properties onTP53mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 databaseHuman Mutation, 2007
- p53-Deficient Cells Rely on ATM- and ATR-Mediated Checkpoint Signaling through the p38MAPK/MK2 Pathway for Survival after DNA DamageCancer Cell, 2007
- Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomasNature, 2007
- Activation of the DNA damage checkpoint and genomic instability in human precancerous lesionsNature, 2005
- DNA damage response as a candidate anti-cancer barrier in early human tumorigenesisNature, 2005
- The Hallmarks of CancerCell, 2000